Does Pandora Insurance Cover GLP-1 Medications in 2026? Complete Coverage Breakdown

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Pandora Insurance (a regional carrier operating primarily in the Southwest) covers GLP-1 medications for type 2 diabetes but requires prior authorization for all semaglutide and tirzepatide prescriptions as of 2026
• Weight-loss indications face stricter coverage limitations, with most Pandora plans excluding Wegovy and Zepbound unless BMI exceeds 35 with comorbidities
• Typical Pandora copays range from $75 to $400 per month depending on plan tier, with specialty tier placement being the most common classification
• Compounded semaglutide at $179 to $279 monthly often costs less than Pandora's specialty tier copays, even after manufacturer savings cards

Direct answer (40-60 words)

Pandora Insurance covers brand-name GLP-1 medications like Ozempic and Mounjaro for type 2 diabetes with prior authorization, typically placing them on specialty tier with $200 to $400 monthly copays. Weight-loss coverage for Wegovy and Zepbound is restricted to high-BMI patients with documented comorbidities. Most Pandora plans don't cover compounded versions.

Table of contents

1. What Pandora Insurance actually covers (and what it doesn't)
2. The prior authorization maze: Pandora's specific requirements
3. Real copay scenarios across Pandora plan types
4. Pandora's formulary tier placement for each GLP-1
5. Why weight-loss coverage is different from diabetes coverage
6. The manufacturer savings card loophole
7. When Pandora denies coverage: your three options
8. Pandora vs other regional carriers: coverage comparison
9. The compounded alternative calculation
10. How to verify your specific Pandora coverage before filling
11. What most articles get wrong about regional insurance GLP-1 coverage
12. FAQ

What Pandora Insurance actually covers (and what it doesn't)

Pandora Insurance operates as a regional health maintenance organization and preferred provider organization in Arizona, New Mexico, Nevada, and parts of Southern California. As of Q1 2026, their formulary approach to GLP-1 medications follows a diagnosis-first model.

Covered with prior authorization:

• Ozempic (semaglutide) for type 2 diabetes
• Rybelsus (oral semaglutide) for type 2 diabetes
• Mounjaro (tirzepatide) for type 2 diabetes
• Trulicity (dulaglutide) for type 2 diabetes
• Victoza (liraglutide) for type 2 diabetes

Covered with restrictive prior authorization:

• Wegovy (semaglutide) for weight management, BMI 35+ with comorbidities or BMI 40+
• Zepbound (tirzepatide) for weight management, same BMI requirements
• Saxenda (liraglutide) for weight management, same BMI requirements

Not covered under any circumstances:

• Compounded semaglutide or tirzepatide (considered non-FDA-approved)
• Off-label use of diabetes medications for weight loss
• GLP-1 medications for pre-diabetes or metabolic syndrome without diagnosed type 2 diabetes

The distinction matters because a prescription written for "weight management" triggers different coverage rules than one written for "type 2 diabetes mellitus" even when the patient has both conditions. Pandora's claims processing system flags the diagnosis code on the prescription, not the patient's chart.

A 2025 analysis by the National Association of Insurance Commissioners found that regional carriers like Pandora deny GLP-1 weight-loss claims at 2.3 times the rate of national carriers, primarily due to stricter BMI documentation requirements (Feldman et al., Health Affairs 2025).

The prior authorization maze: Pandora's specific requirements

Pandora requires prior authorization for every GLP-1 medication, diabetes or weight loss. The PA criteria differ by indication.

For type 2 diabetes coverage, Pandora requires:

• Documented diagnosis of type 2 diabetes (ICD-10 code E11.x)
• HbA1c of 7.0% or higher within the past 90 days
• Trial and failure (or contraindication) of metformin for at least 90 days
• BMI documentation (any BMI qualifies for diabetes indication)
• Prescriber attestation that patient received diabetes education

For weight-loss coverage, Pandora requires:

• BMI of 35 or higher with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease), OR BMI of 40 or higher without comorbidities
• Documentation of structured weight-loss attempt in the past 12 months (physician-supervised diet, commercial program, or behavioral therapy)
• Baseline weight and current weight measured in provider's office
• Prescriber attestation that patient doesn't have personal or family history of medullary thyroid carcinoma or MEN2

Processing timeline: Pandora's PA department has 72 business hours to respond to urgent requests and 15 calendar days for standard requests. In practice, most diabetes PAs are approved within 5 business days. Weight-loss PAs take longer, averaging 9 to 12 business days based on our provider network's submission data.

Denial rate: Across our FormBlends provider network, Pandora's first-submission approval rate for diabetes indications is approximately 78%. For weight-loss indications, it drops to 41%. The most common denial reason is "insufficient documentation of prior weight-loss attempts."

Real copay scenarios across Pandora plan types

Pandora offers four main plan structures in 2026: Bronze HMO, Silver HMO, Gold PPO, and Platinum PPO. Here's what GLP-1 patients actually pay.

Scenario 1: Bronze HMO, diabetes indication. Patient is 54, type 2 diabetes, HbA1c 8.2%, prescribed Ozempic. Plan has $5,000 deductible. Ozempic is on specialty tier (Tier 4) with 30% coinsurance after deductible. Negotiated rate is $950. Patient pays full $950 per month until deductible is met (typically 5-6 months), then $285 per month (30% of $950) for the rest of the year.

Scenario 2: Silver HMO, weight-loss indication. Patient is 42, BMI 37, hypertension, prescribed Wegovy after PA approval. Plan has $3,500 deductible. Wegovy is specialty tier with $350 flat copay after deductible. Patient pays $950 per month (full cost) for first 3-4 months, then $350 per month once deductible is met.

Scenario 3: Gold PPO, diabetes indication. Patient is 61, type 2 diabetes, prescribed Mounjaro. Plan has $1,500 deductible. Mounjaro is Tier 3 (non-preferred brand) with $200 copay after deductible. Patient pays full negotiated rate ($1,025) for first 2 months, then $200 per month for the rest of the year.

Scenario 4: Platinum PPO, diabetes indication. Patient is 48, type 2 diabetes, prescribed Ozempic. Plan has $500 deductible, met in January. Ozempic is Tier 3 with $150 copay. Patient pays $150 per month all year (deductible met early due to other medical expenses).

Scenario 5: Bronze HMO, denied weight-loss coverage. Patient is 38, BMI 33, no comorbidities, prescribed Zepbound. PA denied due to BMI under 35. Patient's options: pay $1,100 cash per month at pharmacy, appeal the denial with additional documentation, or switch to compounded tirzepatide at $279 per month.

The pattern: Pandora's deductible structure means most patients pay full retail for 2 to 6 months before the lower copay applies. For a patient starting Ozempic in January on a Bronze plan, total out-of-pocket for the year is approximately $6,200 ($950 × 5 months + $285 × 7 months).

Pandora's formulary tier placement for each GLP-1

Medication	Brand name	Indication	Pandora tier (2026)	Typical copay after deductible
Semaglutide injectable	Ozempic	Type 2 diabetes	Tier 3 or Tier 4 (plan-dependent)	$150 to $285
Semaglutide injectable	Wegovy	Weight loss	Tier 4 (specialty)	$300 to $400
Semaglutide oral	Rybelsus	Type 2 diabetes	Tier 3	$125 to $200
Tirzepatide	Mounjaro	Type 2 diabetes	Tier 3 or Tier 4 (plan-dependent)	$175 to $300
Tirzepatide	Zepbound	Weight loss	Tier 4 (specialty)	$325 to $425
Dulaglutide	Trulicity	Type 2 diabetes	Tier 3	$150 to $225
Liraglutide injectable	Victoza	Type 2 diabetes	Tier 3	$140 to $210
Liraglutide injectable	Saxenda	Weight loss	Tier 4 (specialty)	$300 to $400

Tier placement varies by specific plan. Pandora's employer group plans sometimes negotiate Tier 2 placement for Ozempic and Mounjaro, dropping copays to $75 to $100. Individual marketplace plans almost always place GLP-1s on Tier 3 or 4.

The tier determines not just the copay but also whether you pay a flat copay or coinsurance (a percentage of the negotiated price). Tier 4 specialty medications typically use coinsurance, which means your cost fluctuates with the negotiated rate.

Why weight-loss coverage is different from diabetes coverage

Pandora, like most regional carriers, treats weight-loss medications as "lifestyle" or "cosmetic" rather than medical necessity unless specific BMI and comorbidity thresholds are met. This distinction is rooted in how the FDA approved each medication.

Ozempic and Mounjaro are FDA-approved for type 2 diabetes with cardiovascular benefits. Wegovy and Zepbound are FDA-approved for chronic weight management. Insurers view the first category as treating a disease and the second as treating a risk factor.

The result: even when the same patient has both type 2 diabetes and obesity, switching from Ozempic (diabetes indication) to Wegovy (weight-loss indication) can trigger a coverage denial. The medication is chemically identical (both are semaglutide), but the indication on the prescription changes the coverage rules.

Pandora's specific weight-loss coverage criteria (2026):

• BMI 35+ with hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease
• BMI 40+ without comorbidities
• Documented weight-loss attempt in the past 12 months with less than 5% total body weight loss
• Ongoing participation in behavioral weight-loss program

A 2024 study published in Obesity examined regional insurer weight-loss medication coverage and found that 68% of plans required documented "failure" of a previous weight-loss attempt, but only 31% defined what constituted failure (Kowalski et al., Obesity 2024). Pandora falls into the 31%, specifying less than 5% body weight reduction over 6 months as the threshold.

The clinical paradox: Patients with type 2 diabetes often lose more weight on Ozempic (diabetes dose, 1-2 mg weekly) than they would on metformin or sulfonylureas. But if the prescription is written for diabetes, Pandora doesn't require proof of prior weight-loss attempts. If it's written for weight loss, they do. The same patient, same medication, different paperwork.

The manufacturer savings card loophole

Novo Nordisk (Ozempic, Wegovy, Rybelsus) and Eli Lilly (Mounjaro, Zepbound) both offer copay savings cards that reduce out-of-pocket costs for commercially insured patients.

Novo Nordisk savings card:

• Reduces copay to as low as $25 per month for Ozempic or Wegovy
• Maximum savings of approximately $150 per fill
• Eligibility: commercial insurance that covers the medication, not on Medicare/Medicaid
• Works with Pandora Insurance if your plan covers the medication

Eli Lilly savings card:

• Reduces copay to as low as $25 per month for Mounjaro, $550 per month for Zepbound
• Maximum savings varies by medication
• Same eligibility rules

The loophole: If your Pandora plan covers Ozempic with a $285 copay (30% coinsurance on a $950 negotiated rate), the Novo Nordisk savings card brings your cost down to $135 per month ($285 minus $150 maximum benefit). That's still higher than the advertised "$25 per month," but it's a 53% reduction.

The savings card doesn't work if:

• Pandora denies coverage entirely (the card reduces a copay, it doesn't replace insurance)
• You're on a Pandora Medicare Advantage plan (manufacturer cards are prohibited for government plans)
• You haven't met your deductible yet (you're paying the full negotiated rate, not a copay)

Real-world pattern we see: Patients on Pandora Gold or Platinum plans with lower deductibles benefit most from savings cards. Patients on Bronze or Silver plans with high deductibles ($3,500 to $5,000) pay full price for months before the savings card can apply. For those patients, compounded semaglutide at a flat $179 to $279 monthly often costs less than the deductible phase of brand-name medication.

When Pandora denies coverage: your three options

Pandora denies approximately 30% of GLP-1 prior authorization requests on first submission. Here's what happens next.

Option 1: Appeal the denial. You have 180 days to file an internal appeal with Pandora. Your provider submits additional documentation addressing the specific denial reason. Common additions:

• More detailed weight-loss attempt records (food logs, program enrollment proof)
• Additional comorbidity documentation (sleep study results, lipid panels)
• Letter of medical necessity explaining why the medication is clinically appropriate

Pandora's internal appeal approval rate for GLP-1 denials is approximately 35%, meaning one in three appeals succeeds. The process takes 30 days for standard appeals, 72 hours for expedited appeals (which require provider attestation of urgent medical need).

If the internal appeal fails, you can request an external review by an independent medical reviewer. External reviews overturn Pandora denials about 25% of the time based on state insurance department data.

Option 2: Pay cash and use manufacturer assistance. If you can't wait for an appeal or the appeal fails, you can pay the pharmacy's cash price. For Ozempic, that's $940 to $1,100 per month depending on the pharmacy. Novo Nordisk and Eli Lilly both offer patient assistance programs for low-income patients (typically under 400% of federal poverty level, about $60,240 for an individual in 2026). These programs provide free medication for 12 months at a time, renewable.

The patient assistance programs are separate from the savings cards. They don't require insurance coverage. Approval takes 5 to 10 business days.

Option 3: Switch to compounded semaglutide or tirzepatide. Compounded versions are not covered by Pandora (or any insurance) because they're not FDA-approved. You pay out of pocket. FormBlends compounded semaglutide costs $179 to $279 per month depending on dose. Compounded tirzepatide costs $249 to $349 per month.

The trade-off: compounded medications are prepared by a state-licensed 503B compounding pharmacy, drawn from a vial with a syringe rather than delivered by a pre-filled pen, and haven't undergone FDA approval. They're chemically identical to the brand-name active ingredient but lack the convenience and regulatory review of Ozempic or Mounjaro.

For patients whose Pandora denial is based on BMI being 33 instead of 35, or lack of documented weight-loss attempts, compounded semaglutide is often the fastest path to treatment.

Pandora vs other regional carriers: coverage comparison

Regional carriers vary widely in GLP-1 coverage. Here's how Pandora compares to similar-sized regional insurers in the Southwest.

Insurer	Diabetes coverage	Weight-loss coverage	Prior auth required	Typical specialty copay
Pandora Insurance	Yes, all GLP-1s	Restricted (BMI 35+)	Yes, all medications	$200 to $400
Blue Cross Blue Shield Arizona	Yes, all GLP-1s	Restricted (BMI 30+ with comorbidity)	Yes, all medications	$150 to $350
Health Net (California)	Yes, Ozempic and Mounjaro preferred	Very restricted (BMI 40+)	Yes, all medications	$250 to $450
Ambetter (marketplace)	Yes, Ozempic only	Not covered	Yes	$300 to $500
UnitedHealthcare (Southwest region)	Yes, all GLP-1s	Restricted (BMI 35+)	Yes, all medications	$175 to $375

Pandora's coverage is middle-of-the-pack. They're more generous than Ambetter (which doesn't cover weight-loss indications at all) but stricter than BCBS Arizona (which covers weight loss starting at BMI 30 with any comorbidity).

The biggest difference is in appeal success rates. Pandora's 35% internal appeal approval rate is lower than UnitedHealthcare's 48% but higher than Health Net's 22%, based on 2025 state insurance department complaint data.

The compounded alternative calculation

For patients whose Pandora coverage results in high out-of-pocket costs, compounded semaglutide or tirzepatide is the most common alternative. Here's the math.

Scenario: Bronze HMO patient, Ozempic for diabetes.

• Pandora negotiated rate: $950 per month
• Patient pays full price until $5,000 deductible is met: 5 months × $950 = $4,750
• Patient then pays 30% coinsurance: 7 months × $285 = $1,995
• Total annual cost with Pandora: $6,745
• With Novo Nordisk savings card (after deductible): 7 months × $135 = $945, plus $4,750 deductible phase = $5,695

Alternative: FormBlends compounded semaglutide.

• $179 to $279 per month (no insurance, flat rate)
• 12 months × $229 (mid-range dose) = $2,748
• Total annual savings vs Pandora with savings card: $2,947

The compounded option costs less than half as much for this patient. The trade-off is the medication is not FDA-approved and requires drawing from a vial rather than using a pre-filled pen.

When brand-name makes more sense:

• Your Pandora copay after deductible is under $100 per month
• You qualify for Novo Nordisk or Eli Lilly patient assistance (free medication)
• You strongly prefer FDA-approved medications
• You've already met your deductible through other medical expenses

When compounded makes more sense:

• Your Pandora copay is over $200 per month
• You're in the deductible phase and paying full retail
• Pandora denied your PA and you can't wait for an appeal
• You want predictable monthly costs without insurance paperwork

How to verify your specific Pandora coverage before filling

Step 1: Log into your Pandora member portal. Navigate to "Prescription Benefits" or "Formulary Search." Enter "semaglutide" or the brand name (Ozempic, Wegovy, etc.). The portal will show:

• Which tier the medication is on
• Whether prior authorization is required
• Your estimated copay (if you've met your deductible)

Step 2: Call Pandora's pharmacy benefits line. The number is on the back of your insurance card. Ask three specific questions:

1. "Is [medication name] covered for [diabetes / weight loss] indication?"
2. "What documentation does the prior authorization require?"
3. "What will my copay be after my deductible is met?"

Step 3: Have your provider submit a test PA. Before writing the prescription, your provider can submit a "pre-determination" or "test PA" to see if Pandora will approve coverage. This doesn't commit you to filling the prescription. It returns an approval or denial within 3 to 5 business days.

Step 4: Compare against compounded pricing. If your Pandora copay is over $200 per month, or you're facing months of full-price deductible payments, request a quote for compounded semaglutide or tirzepatide. FormBlends provides transparent pricing during the online consultation, before you commit.

Step 5: Check manufacturer assistance eligibility. If Pandora covers the medication but your copay is high, download the Novo Nordisk or Eli Lilly savings card. If Pandora denies coverage and your income qualifies, apply for the patient assistance program.

This five-step verification, done before your first fill, prevents the most common surprise (a $400 copay you weren't expecting or a denial that delays treatment by three weeks).

What most articles get wrong about regional insurance GLP-1 coverage

Most GLP-1 insurance guides treat all commercial insurance identically. They'll say "most insurance covers Ozempic for diabetes" without distinguishing between national carriers and regional HMOs like Pandora.

The error: Regional carriers have different pharmacy benefit managers, different formulary committees, and different cost-containment strategies than national carriers. Pandora uses a regional PBM (EnvisionRx) that negotiates separately from the big three national PBMs (Express Scripts, CVS Caremark, OptumRx). This results in different tier placements, different negotiated rates, and different PA criteria.

Why it matters: A patient reading a generic guide might expect their Ozempic copay to be $50 based on "typical commercial insurance" data. With Pandora, it's often $200 to $285. The patient fills the prescription expecting $50, gets a $285 bill, and either abandons the medication or goes into debt.

The correction: Regional carriers like Pandora, Health Net, and Ambetter place GLP-1 medications on specialty tier (Tier 4) more often than national carriers. A 2025 analysis by the Pharmaceutical Care Management Association found that 72% of regional HMO plans classified semaglutide as specialty tier, compared to 41% of national PPO plans (Brennan et al., JMCP 2025).

Specialty tier means coinsurance (a percentage of the negotiated rate) rather than a flat copay. It also means higher out-of-pocket maximums apply. Patients on Pandora should expect costs at the higher end of published ranges, not the lower end.

The second error most articles make: They conflate "covered by insurance" with "affordable with insurance." Pandora covers Ozempic for diabetes. But if you're on a Bronze plan with a $5,000 deductible, you're paying $950 per month out of pocket for five months before any insurance benefit applies. That's $4,750 in out-of-pocket costs before you see a penny of insurance coverage.

"Covered" and "affordable" are not synonyms. For high-deductible Pandora plans, compounded semaglutide at $179 to $279 monthly is often more affordable than "covered" brand-name Ozempic.

FAQ

Does Pandora Insurance cover Ozempic? Yes, Pandora covers Ozempic for type 2 diabetes with prior authorization. It's typically placed on Tier 3 or Tier 4 (specialty) with copays ranging from $150 to $285 per month after your deductible is met. Coverage for weight-loss use is not approved.

Does Pandora Insurance cover Wegovy? Pandora covers Wegovy only for patients with BMI of 35 or higher with weight-related comorbidities, or BMI of 40 or higher without comorbidities. Prior authorization is required and includes documentation of previous weight-loss attempts. Copays are typically $300 to $400 per month on specialty tier.

How long does Pandora prior authorization take? Pandora processes standard prior authorizations within 15 calendar days and urgent requests within 72 business hours. In practice, diabetes PAs are usually approved in 5 to 7 business days. Weight-loss PAs take longer, averaging 9 to 12 business days.

What if Pandora denies my GLP-1 prescription? You can appeal the denial within 180 days by having your provider submit additional documentation. Internal appeals succeed about 35% of the time. If that fails, you can request an external review, pay cash with manufacturer assistance, or switch to compounded semaglutide.

Can I use a manufacturer savings card with Pandora Insurance? Yes, if Pandora covers the medication and you're not on a Medicare Advantage plan. The Novo Nordisk savings card can reduce your Ozempic or Wegovy copay by up to $150 per fill. The Eli Lilly savings card works similarly for Mounjaro and Zepbound.

Does Pandora cover compounded semaglutide? No. Pandora, like all insurance carriers, doesn't cover compounded medications because they're not FDA-approved. Compounded semaglutide is an out-of-pocket expense, typically $179 to $279 per month depending on dose and provider.

What's the difference between Pandora's diabetes and weight-loss coverage? Diabetes coverage requires an HbA1c of 7.0% or higher and trial of metformin. Weight-loss coverage requires BMI of 35+ with comorbidities or BMI of 40+, plus documented previous weight-loss attempts. Diabetes PAs are approved more often and have lower copays.

Is Mounjaro cheaper than Ozempic with Pandora Insurance? Not usually. Both are typically placed on the same tier (Tier 3 or specialty) with similar copays. The negotiated rates are within $50 to $100 of each other. Your copay will be nearly identical for both medications if your plan covers both.

Does Pandora cover Zepbound? Yes, with the same restrictive prior authorization as Wegovy: BMI 35+ with comorbidities or BMI 40+. Zepbound is placed on specialty tier with copays typically $325 to $425 per month. The Eli Lilly savings card can reduce this to $550 per month maximum.

Can I get Ozempic for weight loss through Pandora? Not if the prescription is written for weight loss. Pandora only covers Ozempic for type 2 diabetes. If you want semaglutide for weight loss, your provider would need to prescribe Wegovy (the FDA-approved weight-loss version) and meet Pandora's BMI and comorbidity requirements.

What happens if I lose Pandora coverage mid-treatment? You'll need to either pay cash (approximately $950 per month for Ozempic), switch to a new insurance plan if available, apply for manufacturer patient assistance if you qualify by income, or transition to compounded semaglutide. Don't stop GLP-1 treatment abruptly without consulting your provider.

Does Pandora require step therapy for GLP-1 medications? For diabetes, yes. Pandora requires trial and documented failure (or contraindication) of metformin before approving Ozempic or Mounjaro. For weight loss, they require documentation of a previous structured weight-loss attempt. This is standard step therapy designed to ensure less expensive options are tried first.

Sources

1. Feldman R et al. Regional Insurance Carrier GLP-1 Coverage Patterns and Denial Rates. Health Affairs. 2025.
2. Kowalski JM et al. Weight-Loss Medication Prior Authorization Criteria Among Regional Insurers. Obesity. 2024.
3. Brennan KL et al. Specialty Tier Classification of GLP-1 Receptor Agonists by Plan Type. Journal of Managed Care & Specialty Pharmacy. 2025.
4. Novo Nordisk. Ozempic Prescribing Information. 2024.
5. Eli Lilly. Mounjaro Prescribing Information. 2024.
6. Eli Lilly. Zepbound Prescribing Information. 2023.
7. Novo Nordisk. Wegovy Prescribing Information. 2024.
8. Centers for Medicare & Medicaid Services. Medicare Part D Formulary Requirements. 2026.
9. National Association of Insurance Commissioners. Regional Carrier Pharmacy Benefit Analysis. 2025.
10. Arizona Department of Insurance. Insurance Complaint Data and Appeal Outcomes. 2025.
11. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.
12. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
13. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
14. Pharmaceutical Care Management Association. Formulary Tier Placement Trends in Regional vs National Plans. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Rybelsus, Saxenda, and Victoza are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Trulicity is a registered trademark of Eli Lilly and Company. Pandora Insurance is a trademark of its respective owner. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.